Bedside Results at 20% the cost.

MICELI is a new point-of-care platelet aggregometer that is reliable, portable, inexpensive, and easy to use. And since MICELI monitors at the bedside, decisions can be made in advance, enhancing the patients outcome, long-term prognosis, and reducing any unnecessary procedures or anti-platelet medications.
PORTABLE
With portable aggregometry, we provide results at the point-of-care and when decisions need to be made. The MICELI is ideal for bedside, home, field, and within primary laboratory facilities.

EASY TO USE
At 20% of the cost of aggregometers in the market, the MICELI also comes with the benefit of simplicity. MICELI was designed for ease-of-use and with the injection of a sample, and real-time impedance analysis, results are available in minutes.

The MICELI aggregometer provides portable monitoring for high-risk patients before, during, and after surgical procedures. With platelet count results readily available, MICELI advances reduces the probability of thrombotic events, unnecessary drugs, transfusion therapies, and added surgeries.

Platelet Monitoring, Simplified. Now.
The Market Problem: Platelet Testing Hasn’t Changed in Over 50 Years

01 TIME TO RESULTS
- Transportation to labs with large devices installed
- May take 24 hours or more to and-from clinical laboratories...
- Limits impact on patient results

02 COST OF DEVICES
- Equipment is costly and only available in specialized labs.
- Most cost $40,000 per device or more

03 SPECIALIZED USERS ONLY
- Highly sensitive device
- Requires significant training
- Difficult to operate in primary clinics, clinical departments, or in the field or home

04 LIMITED ASSESSMENT
- Limited biochemical/inflammatory data
- No platelet physiology
- No information on platelet activation & aggregation

Platelet
Activation
Aggregation (Clot Formation)
The Physician’s Problem

Advancing Decision Making and Outcomes for High Risk Patients

- Predicting Surgical Bleeding and Transfusion Needs
- Reducing thrombotic events for patients with cardiac devices
- Anti-platelet therapy management
- Monitoring of platelet dysfunction after cardiopulmonary bypass and complications associated

Platelet Assessment Determines Therapy

Platelet assessment determines therapy and the wrong therapy could cause dire consequences or death. Reasons for activation of clotting must be known.

- BIOCHEMICAL
- MECHANICAL
High-Risk Patients: Clotting & Bleeding

- Pneumonia
- Cancer
- Pulmonary embolus
- Heart Attack (MI)
- Stroke
- Vulnerable plaque
- Mechanical Circulatory support
  - Ventricular Assist
  - Total Artificial Heart
- Cardiac Implant Tx
  - TAVR/Mitral
  - Coronary Stents
  - Arterial Stents
  - Stent Grafts
  - Cancer Therapies
  - Trauma
  - Surgery
  - Medications

1 Million or more will be implanted with stents, and 340,000+ cardiopulmonary bypass patients will require transfusions.

- Addressable Market Size
- 23 MILLION
  
- 1 Million +
- 16 M
  - Peripheral Artery Disease
- 7 M
  - Heart Failure
MICELI is a point-of-care microfluidic platelet aggregometer (monitoring device).

It provides robust platelet data, including mechanical and inflammatory (biochemical) assessments to more readily make advanced patient care decisions...at the bedside.

As a first-to-market product, there is a significant cost savings of 80% for all...

- Patients
- Healthcare providers
- Insurance
No more waiting. Get Real-Time Results.

Until now, real-time platelet function monitoring has not been available in the marketplace, and traditional methods and transfusion algorithms limit detection. The MICELI features stand alone.

- **Portability & Point-of-Care**
  MICELI is small, light, and ideal for use in patient rooms, surgery, and in the field.

- **Full Platelet Data and Assessment!**
  Advance patient decision making can now be made with biochemical, inflammatory, and mechanical data to address patient therapy.

- **Routine & Real-Time Monitoring**
  Ongoing platelet monitoring can now provide routine results or data required during high-risk procedures.

- **Ultra-Fast Testing**
  Platelet testing and results in under 6 minutes.

- **Inexpensive**
  80% cost savings for patients, healthcare providers, and insurance...with superior performance increases.

- **Semi-Automated and Easy to Use**
  Simple sample injection, simple device, and user-friendly software with dashboard-style data.
2015

Discovery & Founding

MICELI is a product developed by PlakDx, LLC, founded and co-invented by:
- Frank LeDuca
- Dr. Marvin Slepian
- Dr. Alberto Redaelli
- John Jackson, MBA

2017

Prototype and Intellectual Property

The MICELI Team worked with the University of Arizona IP development group – Tech Launch Arizona – to validate and patent, in collaboration with the co-inventing institution, Politecnico di Milano, Italy.

Research & Development

Product development is ongoing, with teams in Arizona and in Milan, working to commercialize the minimally viable prototype.

2018: REGULATORY

Pre-Market FDA Submission

The MICELI will qualify as a premarket submission, avoid additional approval time, equivalent to marketed device (21 CFR §807.92(a)(3)), submitted and approved under 510(K) application # k103555.

2019: PRODUCT DEMONSTRATION

Advancing Aggregometry

PlakDx and the creators of the MICELI will begin demonstration for acquisition, licensing, or to further development in partnership.
Partner early and join us.

Our leadership team includes experienced founders of medical device companies, with extensive industry knowledge of diagnostic medicine, disease management, and commercialization of novel therapeutics. The PlakDx executive team has successfully delivered solutions to market, which are in clinical use today.

Frank LaDuca
CEO

John Jackson, MBA
COO

Dr. Marvin Slepian
Chief Medical Officer

Dr. Alberto Redaelli
Co-Founder & Board Member

Is partners with

Center for Accelerated BioMedical Innovation
Seed Opportunity

Capital Investment: Strategic Seed
Research operations, commercialization activities, and other market development, including regulatory needs are funded by research grants. Early seed funding is in need to support development until successful exit, with a target for acquisition or total licensing, within 24 months.

$1.2 MM+

Commercialization Partnerships
Technology Sensitive to Detect Platelet Aggregation or Miniaturized Systems / Lab-on-Chip for Platelet Function Analysis
Partnerships are in discussion to accelerate development with strategic institutions and companies who are currently in-market. Opportunities are available on an institutional and private level, in concert with the Arizona Center for Biomedical Innovation in Arizona.

PROFILE OVERVIEW
Year Founded: 2018
Founders: 4
Co-Inventors: 2
Research Members: 6

Intellectual Property: Patent Pending
Location: Tucson, Arizona and Milan, Italy

Industry Market:
Platelet Aggregation Devices; Hemotology diagnostics; hemostasis management

Partners:
University of Arizona - Arizona Center for Accelerated Biomedical Innovation, Politecnico di Milano
Contact

John Jackson, MBA
Chief Operating Officer and Co-Founder
PlakDx / University of Arizona
John.jackson.shc.arizona.edu
+1 520 971 9397

BOOK A DEMO OR TOUR
2019 Product Brief

Point-of-Care Microfluidic Platelet Aggregometer